Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression

J Cancer Res Clin Oncol. 2007 Oct;133(10):749-59. doi: 10.1007/s00432-007-0220-2. Epub 2007 May 25.


Only few clinical factors predict the prognosis of patients with Ewing tumors. Unfavorable outcome is associated with primary metastatic disease, age > 15 years, tumor volume above 200 ml, and the histological response to chemotherapy. The aim of this study was to elucidate the prevalence and clinical impact of microsatellite instability (MSI) together with the relation between MSI and mismatch repair protein expression in Ewing tumors. DNA from 61 primary Ewing tumors and 11 Ewing tumor cell lines was extracted and microsatellite analysis for the detection of instability or loss of heterozygosity was performed for the five markers of the Bethesda panel BAT25, BAT26, D5S346, D2S123, and D17S250, which represents the established marker panel for the analysis of hereditary non-polyposis colorectal carcinoma (HNPCC) patients. In addition, single nucleotide repeat regions of the two tumor genes BAX and transforming growth factor receptor II (TGFBR2) were also included. All of the 61 samples were suitable for LOH analysis and 55 for the determination of MSI-status. LOH of these microsatellite markers was detected in 9 of the 61 patients (14.8%). Over all, genetic instability, i.e. MSI and/or LOH, was detected in 17 tumors (27.9%). One out of the 11 tumor cell lines (STA ET1) was characterized by instability of all the five Bethesda markers, while from primary tumor samples, only one showed MSI in more than one microsatellite marker (D5S346 and D17S250, MSI-high). Eight of the fifty-five patients (14.5%) showed instability of one microsatellite locus (MSI-low). No instability was detected in BAT26, D2S123, BAX and TGFBR2. There was no significant correlation between MSI and loss of expression of mismatch repair proteins MLH1, MSH2, or MSH6. The impairment of the p53 signaling pathway (expression of TP53 and/or MDM2 by immunohistochemistry) was significantly associated with reduced overall survival (15 of 49 patients (30.6%), P = 0.0410, log-rank test). We conclude that MSI is not prevalent in Ewing tumor and that the nature of instability differs from the form observed in colorectal carcinoma, the model tumor of MSI. This is documented by the different pattern of MSI (no BAT26 instability) in Ewing tumors and the lack of a strict correlation between MSI-high and loss of expression of MSH2, MSH6 and MLH1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / biosynthesis*
  • Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis
  • DNA Mutational Analysis
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Loss of Heterozygosity
  • Microsatellite Instability*
  • MutL Protein Homolog 1
  • MutS Homolog 2 Protein / biosynthesis*
  • Nuclear Proteins / biosynthesis*
  • Oncogene Proteins, Fusion / biosynthesis
  • Polymerase Chain Reaction
  • Proto-Oncogene Protein c-fli-1
  • RNA-Binding Protein EWS
  • Sarcoma, Ewing / genetics*
  • Sarcoma, Ewing / metabolism*
  • Sarcoma, Ewing / mortality
  • Survival Analysis
  • Transcription Factors / biosynthesis
  • Tumor Suppressor Protein p53 / biosynthesis


  • Adaptor Proteins, Signal Transducing
  • Cyclin-Dependent Kinase Inhibitor p16
  • EWS-FLI fusion protein
  • MLH1 protein, human
  • Nuclear Proteins
  • Oncogene Proteins, Fusion
  • Proto-Oncogene Protein c-fli-1
  • RNA-Binding Protein EWS
  • Transcription Factors
  • Tumor Suppressor Protein p53
  • MSH2 protein, human
  • MutL Protein Homolog 1
  • MutS Homolog 2 Protein